103589-67-9

Upstream product

• 88745-35-1 4-Cyano-2,3,5,6-tetrahydro-7H-cyclopenta<1,2-c>pyridin-3-one 
• 5660-83-3 2-cyclopentylidene malononitrile 
• 68-12-2 N,N-dimethyl-formamide 
• 120-92-3 cyclopentanone 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 1644599-75-6 methyl 1-(4-phenyl-1H-1, 2,3-triazol-1-yl)-7,8-dihydro-6H-cyclopenta[d]thieno[2,3-b]pyridine-2-carboxylate 
• 2409124-08-7 3-isopropyl-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carbonitrile 
• 2409124-11-2 3-isopropyl-6,7-dihydro-5H-cyclopenta[c]pyridine-4-amine 
• 2409124-07-6 3-(prop-1-en-2-yl)-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carbonitrile 
• 2676862-51-2 3-isopropyl-1-methoxy-6,7-dihydro-5H-cyclopenta[c]pyridin-4-amine 
• 2676862-50-1 1-bromo-3-isopropyl-6,7-dihydro-5H-cyclopenta[c]pyridin-4-amine 
• 103589-69-1 3-(3-Isopropyl-2-phenyl-oxazolidin-5-ylmethoxy)-6,7-dihydro-5H-[2]pyrindine-4-carbonitrile 

Relevant academic research and scientific papers

ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS

Disclosed herein are certain acetamido derivatives that are DNA Polymerase Theta (Polθ) inhibitors of Formula (I). Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.

THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula (I), where R1, R2, R3, R4, R5, R5', R6, R7, X, m, and n are described herein.

Synthesis of methyl 3-azidothieno[2,3-b]pyridine-2-carboxylates and application of the huisgen reaction

The preparation of new substituted methyl 3-azidothieno[2,3-b]pyridine carboxylates by azotization of methyl 3-aminothieno[2,3-b]pyridine and subsequent treatment with sodium azide is described. Via Huisgen's 1,3-dipolar cycloaddition between substituted alkynes and the prepared azides, methyl 1,2,3-triazolo-thieno[2,3-b]pyridine carboxylates have been obtained.

Synthesis and bioactivity of novel amino-pyrazolopyridines

Here we describe the synthesis and biological activity of novel amino-pyrazolopyridines with anti-NF-κB and pro-apoptotic potential. α-Methylene ketones were used as a starting point for synthesis of amino-pyrazolopyridine 3. The alkylidene malononitriles 1 were obtained by the Knoevenagel reaction of ketones with malononitriles. Vilsmeier-Haack reaction allowed direct access to 2-chloro-3-cyanopyridines 2. Those products, by refluxing with hydrazine hydrate, allowed cyclization to amino-pyrazolopyridines 3a-g, which were not previously described in the literature. Bioactivity results indicated that amino-pyrazolopyridines 3a, 3b and 3g induced apoptotic cell death in K562 cancer cells with an IC50 of 36.5 ± 3.9 μM, 27.6 ± 4.5 μM and 35.0 ± 2.3 μM, respectively, after 72 h. In addition, compounds 3a, 3b and 3g exerted NF-κB inhibition activity with an IC50 of 4.7 ± 1.6 μM, 6.9 ± 1.9 μM and 39.8 ± 3.9 μM, respectively, after 8 h in K562 cells activated with TNFα. Compounds 3b and 3g showed interesting differential toxicity as viability of peripheral blood mononuclear cells (PBMCs) from healthy donors remained largely unaffected by this treatment.

A one-pot synthesis of 2-chloronicotinonitriles and fused 2-chloro-3-cyanopyridines

2-Chloronicotinonitriles (2a-d) and fused bi- and tricyclo-2-chloro-3-cyanopyridines (2e-h) are obtained from alkylidenemalononitriles (1a-h) by Vilsmeier reaction.Generation in situ of an aldehyde equivalent species in the Vilsmeier reaction at the γ-carbon with respect to the nitrile carbon of the alkylidenemalononitriles, followed by cylization, both occurring in one-pot, are presumed to be involved in the pyridoannulation.